• Angiotensin 1/2 (5-7): Deep Profiling in Cardiovascular and

  2026-05-13

  Explore how Angiotensin 1/2 (5-7) advances renin-angiotensin system research and emerging SARS-CoV-2 applications. This in-depth article uniquely unpacks molecular mechanisms, protocol best practices, and translational implications.

• PPM-18 Enhances Inflammation and Sepsis Research Workflows

  2026-05-13

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) streamlines targeted NF-κB pathway inhibition and iNOS suppression for robust, reproducible inflammation and sepsis studies. As a rigorously validated APExBIO compound, it enables precise modulation of immune responses, outperforming conventional reagents in both cellular and in vivo models.

• 5hmC’s Genomic Context Functions in Rice Drought Response

  2026-05-12

  This study delivers the first single-base resolution map of 5-hydroxymethylcytosine (5hmC) in rice, revealing its context-dependent regulatory impact on gene expression during drought adaptation. The findings clarify 5hmC's dynamic, genomic-location-specific roles and its interplay with classical methylation, providing a critical framework for future plant epigenetic and resilience engineering research.

• LY2886721: Precision BACE1 Inhibition and Synaptic Safety In

  2026-05-12

  Explore the role of LY2886721 as a potent BACE inhibitor in Alzheimer's disease research, with a unique focus on synaptic safety and optimal assay design. This article provides a deeper analysis of partial BACE1 inhibition and its translational value.

• HyperScript RT SuperMix for qPCR: Advancing Neurodegeneratio

  2026-05-11

  Explore how HyperScript RT SuperMix for qPCR enables precise cDNA synthesis from challenging RNA templates, empowering gene expression analysis in neurodegeneration research. This article uniquely bridges latest mitophagy findings with practical assay optimization.

• Potassium Channel Blockade Alters Renal Blood Flow in Septic

  2026-05-11

  This study investigates how blocking specific potassium channels affects renal vascular responses to vasoactive agents in a rat sepsis model. The findings reveal that KCa1.1 and Kir6.1 channel inhibition can exacerbate reductions in renal blood flow when combined with norepinephrine or phenylephrine, highlighting the importance of potassium channel function in sepsis-related kidney dysfunction.

• Phosbind Acrylamide: Precise Phosphate-Binding for SDS-PAGE

  2026-05-10

  Phos binding reagent (Phosbind) acrylamide is a specialized phosphate-binding reagent that enables antibody-free, highly selective detection of protein phosphorylation via SDS-PAGE mobility shifts. This product streamlines protein phosphorylation analysis for targets between 30–130 kDa and eliminates the need for phospho-specific antibodies, making it ideal for signal transduction studies.

• Ziprasidone Inhibits GOT1, Disrupting Glutamine Metabolism i

  2026-05-09

  The referenced study identifies ziprasidone as a novel non-competitive inhibitor of GOT1, reprogramming glutamine metabolism and redox homeostasis in pancreatic ductal adenocarcinoma (PDAC) cells. This mechanistic insight reveals new therapeutic avenues for targeting metabolic vulnerabilities in PDAC.

• Asunaprevir (BMS-650032): Potent HCV NS3 Protease Inhibitor

  2026-05-09

  Asunaprevir (BMS-650032) is a highly potent, orally administered inhibitor of the hepatitis C virus (HCV) NS3 protease, exhibiting broad genotype coverage and nanomolar efficacy. Developed by APExBIO, it is integral to research on HCV RNA replication inhibition and antiviral strategies for hepatitis C virus infection.

• Pioglitazone (SKU B2117): Reliable Pathways for Cell Viabili

  2026-05-08

  Explore how Pioglitazone (SKU B2117) from APExBIO tackles common laboratory challenges in cell viability, proliferation, and inflammatory modulation assays. This article delivers scenario-driven guidance rooted in peer-reviewed evidence and real-world protocol optimization, enabling biomedical researchers to achieve reproducible, data-backed results with confidence.

• Canagliflozin Hemihydrate: Applied Strategies in Glucose Met

  2026-05-07

  Canagliflozin hemihydrate stands out for its precision in targeting renal glucose reabsorption, enabling advanced studies in diabetes and metabolic disorder pathways. This article delivers actionable workflows, troubleshooting guidance, and contextualizes its specificity versus mTOR pathway inhibition, optimizing research strategy and reliability.

• XAV-939: Precision Tankyrase Inhibitor for Advanced Wnt Rese

  2026-05-07

  XAV-939 (NVP-XAV939) is a benchmark tankyrase 1/2 inhibitor enabling robust and reproducible Wnt/β-catenin pathway modulation in cancer, fibrosis, and stem cell differentiation studies. Its nanomolar potency and proven utility in combinatorial screening, reprogramming, and osteogenic workflows make it a linchpin for translational research.

• PDHA1 Acetylation Suppresses Cuproptosis and Drug Response i

  2026-05-06

  This study reveals how PDHA1-mediated acetylation signaling suppresses cuproptosis, attenuating the efficacy of anti-androgen therapy in castration-resistant prostate cancer (CRPC). The mechanistic link between mitochondrial metabolism, epigenetic regulation, and copper-dependent cell death highlights new avenues for overcoming therapy resistance.

• Reliable Protein Extraction: Protease and Phosphatase Inhibi

  2026-05-06

  This article addresses prevalent laboratory challenges in protein extraction and post-translational modification preservation, offering scenario-driven guidance for using the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O), SKU K4006. Drawing on experimental best practices and recent literature, it demonstrates how APExBIO’s formulation ensures reproducible data quality in cell viability and signaling assays.

• Calnexin-Dependent Modulation of CFTR Variant Rescue in CF

  2026-05-05

  Tedman et al. systematically dissect how the ER chaperone calnexin modulates the expression and pharmacological rescue of over 200 CFTR variants. Their deep mutational scanning reveals domain-specific requirements for calnexin in CFTR folding and corrector responsiveness, with implications for personalized cystic fibrosis therapy design.

446 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page